


PHARMACEUTICAL 2018

Paratek Pharmaceuticals Inc. Rank 216 of 342





DARATEK



PHARMACEUTICAL 2018



Paratek Pharmaceuticals Inc. Rank 216 of 342

The relative strengths and weaknesses of Paratek Pharmaceuticals Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Paratek Pharmaceuticals Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 72% points. The greatest weakness of Paratek Pharmaceuticals Inc. is the variable Liabilities, Non-Current, reducing the Economic Capital Ratio by 110% points.

The company's Economic Capital Ratio, given in the ranking table, is 43%, being 2.5% points below the market average of 46%.

Input Variable	Value in 1000 USD
Assets, Current	160,486
Cost of Goods Sold	0
Intangible Assets	971
Liabilities, Current	16,789
Liabilities, Non-Current	64,360
Other Assets	530
Other Compr. Net Income	-142
Other Expenses	5,991
Other Liabilities	71
Other Net Income	1,343
Other Revenues	12,616
Property and Equipment	1,711
Research and Development	60,072
Selling, General and Administrative Expense	36,965

Output Variable	Value in 1000 USD
Assets	163,698
Liabilities	81,220
Expenses	103,028
Revenues	12,616
Stockholders Equity	82,478
Net Income	-89,069
Comprehensive Net Income	-89,140
Economic Capital Ratio	43%

